ONVO vs. MBOT, AIM, OKYO, BCLI, ACHL, QNCX, ESLA, NKGN, SRZN, and INKT
Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Microbot Medical (MBOT), AIM ImmunoTech (AIM), OKYO Pharma (OKYO), Brainstorm Cell Therapeutics (BCLI), Achilles Therapeutics (ACHL), Quince Therapeutics (QNCX), Estrella Immunopharma (ESLA), NKGen Biotech (NKGN), Surrozen (SRZN), and MiNK Therapeutics (INKT). These companies are all part of the "medical" sector.
Organovo (NASDAQ:ONVO) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk.
Organovo has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.
Microbot Medical has lower revenue, but higher earnings than Organovo. Microbot Medical is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Microbot Medical received 150 more outperform votes than Organovo when rated by MarketBeat users. Likewise, 70.61% of users gave Microbot Medical an outperform vote while only 50.13% of users gave Organovo an outperform vote.
In the previous week, Organovo had 2 more articles in the media than Microbot Medical. MarketBeat recorded 4 mentions for Organovo and 2 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 1.89 beat Organovo's score of 0.94 indicating that Microbot Medical is being referred to more favorably in the news media.
Microbot Medical's return on equity of -149.24% beat Organovo's return on equity.
8.2% of Organovo shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 5.0% of Organovo shares are owned by company insiders. Comparatively, 10.6% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Microbot Medical has a consensus price target of $7.00, suggesting a potential upside of 593.07%. Given Microbot Medical's higher possible upside, analysts clearly believe Microbot Medical is more favorable than Organovo.
Summary
Microbot Medical beats Organovo on 12 of the 15 factors compared between the two stocks.
Get Organovo News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organovo Competitors List
Related Companies and Tools
